Mizuho Securities Cuts Price Target on Exact Sciences (EXAS) to $12 Following USPSTF Cologuard Guidelines
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Wall St rebounds after Fed's first rate hike in years as oil, Treasury yields dip
- Oil falls 2% to one-week low as Middle East supply disruption fears ease
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- Paradium AI (PAAI) Halted, News Pending
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Exact Sciences to Host Webcast and Conference Call Regarding U.S. Preventive Services Task Force Draft Recommendations
October 6, 2015 7:50 AM EDTMADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will host a webcast and conference call to discuss the U.S. Preventive Services Task Force release of its draft recommendations regarding colorectal cancer screening.
U.S. Preventive Services Task Force Webcast and Conference Call Details
  Date:  Tuesday, Oct. 6, 2015 Time: 9 a.m. ET, 8 a.m. CT... MoreCologuard® Included as Alternative Screening Test under Draft USPSTF Guidelines
October 5, 2015 8:21 PM EDTMADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences (Nasdaq: EXAS) issued the following statement today following the U.S. Preventive Services Task Force (USPSTF) draft recommendation statement for colorectal cancer screening.
USPSTF included Cologuard in the draft guidelines as an alternative screening test, along with CT colonography. The draft guidelines recommend an A rating for colorectal cancer screening starting at age 50 and continuing until age 75.... More
